JOURNAL CONTENT
CONTACT

Submission of the manuscript is online via e-mail
ecgarticle@gmail.com or
cholerez@mail.ru

Tel: +7 903 250 5288

Editorial Correspondence e-mail
gastrossr@gmail.com


Publishing, Subscriptions, Sales and Advertising, Correspondence e-mail
journal@cniig.ru

Tel: +7 917 561 9505

THE RULES OF SUBMITTING AN ARTICLE

READ

Scimago Journal & Country Rank

SCImago Journal & Country Rank

REVIEW

    1. Ogarev Mordovia State University (Saransk, Russian Federation)

    Keywords:liver,pregnancy,autoimmune hepatitis,diagnosis,treatment

    Abstract:Presents recent data on autoimmune hepatitis, variants of its clinical symptoms and course. Special attention is paid to the disease during pregnancy and in the postpartum period. Presents current local and international guidelines on the management of pregnant women with autoimmune hepatitis, the possible basic and alternative drug treatment of the disease during pregnancy. The authors present their clinical observations of the author over the course of pregnancy in patients with autoimmune hepatitis.

      1. Рекомендации EASL по лечению аутоиммунного гепатита. J. Hepatol., 2015, vol. 63, pp. 971-1004.
      2. Longhi M. S., Ma Y., Mieli-Vergani G., Vergani D. Aetiopathogenesis of autoimmune hepatitis. J Autoimmun., 2009, vol. 17, no. 9, pp.186-189.
      3. Schramm C., Wahl I., Weiler-Normann C. et al. Health-related quality of life, depression, and anxiety in patients with autoimmune hepatitis. J. Hepatol., 2014, vol. 60, pp. 618-624.
      4. Wolf D. C., Raghuraman U. V. Autoimmune Hepatitis. New York Medical College, St John Medical Center. 2011.[Medline].
      5. Czaja A. J. Special clinical challenges in autoimmune hepatitis: the elderly, males, pregnancy, mild disease, fulminant onset, and nonwhite patients. Semin Liver Dis., 2009, vol. 29, no. 3, pp. 315-330.
      6. Takahashi H., Zeniya M. Acute presentation of autoimmune hepatitis: Does it exist? A published work review. Hepatol Res., 2011, vol. 41, pp. 498-504.
      7. Zachou K., Muratori P., Koukoulis G. K. et al. Review article: autoimmune hepatitis - Current management and challenges. Aliment Pharmacol Ther., 2013, vol. 38, pp. 887-913.
      8. Czaja A. J., Lindor K. D. Failure of budesonide in a pilot study of treatment-dependent autoimmune hepatitis. Gastroenterology, 2000, vol. 119, pp. 1312-1316.
      9. Czaja A. J. Drug choices in autoimmune hepatitis: part A-Steroids. Expert Rev Gastroenterol Hepatol., 2012, vol. 6, pp. 603-615.
      10. Gronbæk L., Vilstrup H., Jepsen P. Autoimmune hepatitis in Denmark: incidence, prevalence, prognosis, and causes of death. A nationwide registry-based cohort study. J Hepatol., 2014, vol. 60, pp. 612-617.
      11. Manns M. P., Lohse A. W., Vergani D. «Autoimmune hepatitis - Update 2015». Journal of Hepatology, 2015, vol. 62, no. 1, S 100-S 111.
      12. Sex Bias in Experimental Immune-Mediated, Drug-Induced Liver Injury in BALB/c Mice: Suggested Roles for Tregs, Estrogen, and IL-6 - PLoS One, doi:10.1371/journal.pone.0061186, April 2013
      13. Obermayer-Straub P., Perheentupa J., Braun S. et al. Hepatic autoantigens in patients with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. Gastroenterology, 2001, vol. 121, pp. 668-677.
      14. AASLD PRACTICE GUIDELINES Diagnosis and Management of Autoimmune Hepatitis, 2010.
      15. Rigopoulou E. I., Dalekos G., Bogdanos D. P. How common are connective tissue disorders in patients with autoimmune hepatitis? Semin Arthritis Rheum., 2007, vol. 36, p.332.
      16. Teufel A., Weinmann A., Kahaly G. J. et al. Concurrent autoimmune diseases in patients with autoimmune hepatitis. J Clin Gastroenterol., 2010, vol. 44, pp. 208-213.
      17. Ивашкин В. Т., Морозова М. А., Маевская М. В., Буеверов А. О. Современные терапевтические схемы лечения аутоиммунного гепатита. РЖГГК, 2009, № 4, с. 4-12.
      18. Heneghan M. A., Norris S. M., O’Grady J.G. et al. Management and outcome of pregnancy in autoimmune hepatitis. Gut, 2001, vol. 48, pp. 97-102.
      19. Schramm C., Herkel J., Beuers U. et al. Pregnancy in autoimmune hepatitis: outcome and risk factors. Am J Gastroenterol., 2006, vol. 101, pp. 556-560.
      20. Werner M., Bjornsson E., Prytz H. et al. Autoimmune hepatitis among fertile women: strategies during pregnancy and breastfeeding? Scand J Gastroenterol., 2007, vol. 42, pp. 986-991.
      21. Westbrook R. H., Yeoman A. D., Kriese S., Heneghan M. A.Outcomes of pregnancy in women with autoimmune hepatitis. J Autoimmun., 2012, vol. 38, J239-244.
      22. Varma R. R., Michelsohn N. H., Borkowf H. I., Lewis J. D. Pregnancy in cirrhotic and noncirrhotic portal hypertension. Obstetrics and Gynecology, 1977, vol. 50, no. 2, pp. 217-222.
      23. Sandhu B. S., Sanyal A. J. Pregnancy and liver disease. Gastroenterol Clin North Am, 2003, vol. 32, pp. 407-436.
      24. Schreyer P., Caspi E., El-Hindi J.M., Eshchar J. Cirrhosis-pregnancy and delivery: a review. Obstet Gynecol Surv., 1982, vol. 37, pp. 304-312.
      25. Buchel E., Van Steenbergen W., Nevens F., Fevery J. Improvement of autoimmune hepatitis during pregnancy followed by flare-up after delivery. Am J Gastroenterol., 2002, vol. 97, pp. 3160-3165.
      26. Samuel D., Riordan S., Strasser S. et al. Severe autoimmune hepatitis first presenting in the early post partum period. Clin Gastroenterol Hepatol., 2004, vol. 2, pp. 622-624.
      27. Muratori P., Loffreda S., Muratori L. et al. Spontaneous remission of autoimmune hepatitis during pregnancy. Dig Liver Dis., 2002, vol. 34, pp. 608-609.
      28. Terrabuio D. R., Abrantes-Lemos C.P., Carrilho F. J., Cancado E. L. Follow-up of pregnant women with autoimmune hepatitis: the disease behavior along with maternal and fetal outcomes. J Clin Gastroenterol., 2009, vol. 43, pp. 350-356.
      29. Westbrook R. H., Dusheiko G., Williamson A. Болезни печени у беременных. Journal of Hepatology, 2016, vol. 64, pp. 993-945 (Русское издание, Т. 2, № 3)
      30. Adamowicz R., Trzeciak-Supel E., Smolarczyk R. et al. Subsequent pregnancy (twin) in woman with autoimmunological hepatitis. Ginekol Pol., 2005, vol. 76, pp. 742-746.
      31. Еремина Е. Ю. Лекарственный гепатит у беременных. Врач, 2015, № 8, с. 11-13.
      32. Gatselis N. K., Zachou K., Papamichalis P. et al. Comparison of simplified score with the revised original score for the diagnosis of autoimmune hepatitis: a new or a complementary diagnostic score? Dig Liver Dis, 2010, vol. 42, pp. 807-812.
      33. Еремина Е. Ю. Лекарственный гепатит у беременных. Проблемы женского здоровья, 2011, № 4, Т. 6, с. 46-55.
      34. Еремина Е. Ю. Аутоиммунные заболевания печени и беременность. Практическая медицина, 2011, № 6, Т. 54, с. 12-18.
      35. Castiella A., Zapata E., Lucena M. I., Andrade R. J. Drug-induced autoimmune liver disease: a diagnostic dilemma of an increasingly reported disease. World J Hepatol., 2014, vol. 6, pp. 160-168.
      36. Weiler-Normann C., Schramm C. Drug induced liver injury and its relationship to autoimmune hepatitis. J Hepatol., 2011, vol. 55, pp. 747-749.
      37. Bjornsson E., Talwalkar J., Treeprasertsuk S. et al. Drug-induced autoimmune hepatitis: clinical characteristics and prognosis. Hepatology, 2010, vol. 51, pp. 2040-2048.
      38. Ивашкин В. Т., Буеверов А. О., Маевская М. В., Абдулганиева Д. И. Клинические рекомендации по диагностике и лечению аутоиммунного гепатита. М., 2013.
      39. Ashima M., Kymberly D., Vaidehi R. Autoimmune Hepatitis: A Review of Current Diagnosis and Treatment Hepatitis Research and Treatment. 2011, Article ID 390916, 11 pages doi:10.1155/2011/390916
      40. Candia L., Marquez J., Espinoza L. R. Autoimmune hepatitis and pregnancy: a rheumatologist’s dilemma. Semin Arthritis Rheum., 2005, vol. 35, no. 1, pp. 49-56.
      41. Manns M. P., Czaja A. J., Gorham J. D. et al. Diagnosis and management of autoimmune hepatitis. Hepatology, 2010, vol. 51, pp. 2193-2213.
      42. Czaja A. J., Freese D. K. AASLD practice guidelines. Diagnosis and treatment of autoimmune hepatitis. Hepatology, 2002, vol. 36, no. 2, pp. 479-497.
      43. Murray-Lyon I.M., Stern R. B., Williams R. Controlled trial of prednisone and azathioprine in active chronic hepatitis. Lancet, 1973, vol. 1, pp. 735-737.
      44. Summerskill W. H., Korman M. G., Ammon H. V., Baggenstoss A. H. Prednisone for chronic active liver disease: dose titration, standard dose, and combination with azathioprine compared. Gut, 1975, vol. 16, pp. 876-883.
      45. De Vries F., Bracke M., Leufkens H. G. et al. Fracture risk with intermittent high-dose oral glucocorticoid therapy. Arthritis Rheum., 2007, vol. 56, pp. 208-214.
      46. Czaja A. J. Safety issues in the management of autoimmune hepatitis. Expert Opin Drug Safety, 2008, vol. 7, pp. 319-333.
      47. Chambers C. D., Tutuncu Z. N., Johnson D. et al. Human pregnancy safety for agents used to treat rheumatoid arthritis: adequacy of available information and strategies for developing post-marketing data. Arthritis Res Ther., 2006, vol. 8, p. 215.
      48. Francella A., Dyan A., Bodian C., et al. The safety of 6-mercaptopurine for childbearing patients with inflammatory bowel disease: a retrospective cohort study. Gastroenterology, 2003, vol. 124, pp. 9-17.
      49. Casanova M. J., Chaparro M., Domenech E. et al. Safety of thiopurines and anti-TNF-alpha drugs during pregnancy in patients with inflammatory bowel disease. Am J Gastroenterol., 2013, vol. 108, pp. 433-440.
      50. Angelberger S., Reinisch W., Messerschmidt A. et al. Long-term follow-up of babies exposed to azathioprine in utero and via breastfeeding. J Crohns Colitis, 2011, vol. 5, pp. 95-100.
      51. Manns M. P., Woynarowski M., Kreisel W. et al. European AIH-BUC Study Group: budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis. Gastroenterol., 2010, vol. 139, no. 4, pp. 1198-1206.
      52. Woynarowski M., Nemeth A., Baruch Y. et al. European AIH-BUC Study Group. Budesonide versus prednisone with azathioprine for the treatment of autoimmune hepatitis in children and adolescents. J. Pediatr., 2013, vol. 163, no. 5, pp. 1347-1353.
      53. Hempfling W., Grunhage F., Dilger K. et al. Pharmacokinetics and pharmacodynamic action of budesonide in early- and late-stage primary biliary cirrhosis. Hepatology, 2003, vol. 38, no. 1, pp. 196-202.
      54. Mederacke I., Helfritz F., Puls F. et al. Budd-Chiari syndrome after treatment with budesonide in a cirrhotic patient with autoimmune hepatitis. Ann Hepatol., 2012, vol. 11, no. 1, pp. 143-144.
      55. Christopher V., Al-Chalabi T., Richardson P. D. et al. Pregnancy outcome after liver transplantation: a single-center experience of 71 pregnancies in 45 recipients. Liver Transpl., 2006, vol. 12, pp. 1138-1143.
      56. Christopher V., Al-Chalabi T., Richardson P. D. et al. Pregnancy outcome after liver transplantation: a single-center experience of 71 pregnancies in 45 recipients. Liver Transpl., 2006, vol. 12, pp. 1138-1143.
      57. Еремина Е. Ю., Машарова А. А. Заболевания органов пищеварительной системы у беременных. Саранск, 2009. 200 с.
      58. Еремина Е. Ю. Аутоиммунные заболевания печени и беременность: информация для практического врача. Медицинский альманах, 2011, № 6, Т. 19, c.82-87.
      59. Marten W., Einar B., Hanne P. et al. Autoimmune hepatitis among fertile women: strategies during pregnancy and breastfeeding? Scand J Gastroenterol., 2007, vol. 42, no. 8, pp. 986-991.
      60. Christensen L. A., Dahlerup J. F., Nielsen M. J. et al. Azathioprine treatment during lactation. Aliment Pharmacol Ther., 2008, vol. 28, pp. 1209-1213.
      61. Tripathi D., Neuberger J. Autoimmune hepatitis and liver transplantation: indications, results, and management of recurrent disease. Semin Liver Dis., 2009, vol. 29. No. 3, pp. 286-96.
     


    Full text is published :
    Eremina E.Yu. AUTOIMMUNE HEPATITIS AND PREGNANCY. Experimental and Clinical Gastroenterology Journal. 2017;141(05):48-56
    Read & Download full text

    1. Veltischev Research ; Clinical Institute for Pediatrics at the Pirogov Russian National Research Medical University (Moscow, Russian Federation)

    Abstract:Objective: a prospective, open, observational study to assess the tolerability and efficacy of multicomponent probiotics containing Lactobacillus acidophilus, Lactobacillus reuteri, Bifidobacterium lactis and Lactobacillus acidophilus LA-14, Lactobacillus plantarum LP-115, Bifidobacterium longum BB 536 with functional gastrointestinal disorders in early aged children and in frequently ill children. Methods: the first part of the study included 35 infants with functional gastrointestinal disorders during the onset of intestinal colic, dentition, transition from breast to artificial feeding: 25 children received a multicomponent probiotic, 10 children made up a control group. The second part of the study included 40 patients aged 18-24 months during and after taking antibiotics due to virus-bacterial diseases: 20 children received a probiotic and 20 children with similar problems and diseases made up a control group. The study design included 2 visits with an assessment of clinical signs, a coprological study, a quantitative microbiological seeding of feces for the maintenance of microorganisms. The levels of sIgA and lysozyme in coprofiltrates were determined. Results: as a result of assessing the tolerability and clinical effectiveness of the multicomponent probiotic usage in children of the first group with functional gastrointestinal disorders, a good tolerance of the probiotic was established. The improvement of the gastrointestinal tract with its dysfunction associated with dentition, transition from breast to artificial feeding was noted. The probiotic usage in a standard dosage and duration of 2 weeks resulted in clinical (normalization of stool frequency and consistency and other characteristic manifestations: regurgitation, flatulence, frequency and intensity of colic) and laboratory improvement. In the group of children who received the multicomponent probiotic in combination with an antibiotic, an active immunological reaction of the children’s organism to the viral-bacterial disease was noted the increasing concentration of sIgA and lysozyme in coprofiltrates. Conclusion: The multicomponent probiotic containing Lactobacillus acidophilus, Lactobacillus reuteri, Bifidobacterium lactis and Lactobacillus acidophilus LA-14, Lactobacillus plantarum LP-115, Bifidobacterium longum BB 536, can be recommended for widespread usage in early aged children with functional gastrointestinal disorders including disturbance of the stool, flatulence, intestinal colic, as well as in unfavorable conditions, which are associated with a risk of microbiocenosis and immunological intestinal tolerance disorders. Preparations should be used from the first day of antibiotic therapy and continue for 2-3 weeks after the end of admission. The study showed good tolerability of the probiotic, there were no side and undesirable effects.

      1. Кушнарева М. В. Дисбактериоз кишечника у новорожденных и детей первого года жизни. Приложение к журналу Материалы II Российского конгресса «Современные технологии в педиатрии и детской хирургии». - Москва, 2003. - С. 181-185.
      2. Бактериологическая диагностика дисбактериоза кишечника у онкологических больных. (Методические рекомендации)/Состав. А. З. Смолянская, О. П. Марко. - М., 1983. - 26 с.
      3. Лабинская А. С. Микробиология с техникой микробиологических исследований (Справочник). - M.: Медицина, 1978. - С. 164-166.
      4. Барановский А. Ю., Кондрашина Э. А. Дисбактериоз и дисбиоз кишечника. - СПб., 2000. - 209 с.
      5. Хавкин А. И. Микрофлора пищеварительного тракта. - М.: Фонд социальной педиатрии. - 2006. - 414 с.
      6. Дисбиоз кишечника. Руководство по диагностике и лечению./ Под ред. Проф. Ткаченко Е. И., проф. Суворова А. Н. - СПб.: Спецлит, 2007. - 238 с.
      7. Корниенко Е. А. Современный подход к коррекции кишечной микробиоты у детей. Методическое пособие для врачей. - СПб, 2007. - 56 с.
      8. Хавкин А. И. Нарушение микробиоценоза кишечника у детей (Методическое пособие). - М., 2016. - 48 с.
      9. Gut microflora. Digestive physiology and pathology.//Edited by: J-C. Rambaud, J-P. Buts, G. Corthier, B. Flourie. - John Libbey Eurotex, Paris. - 2008, - 247 p.
      10. Хавкин А. И., Пампура А. Н., Комарова О. Н., Чусляева А. А. Роль пробиотиков в комплексной терапии атопического дерматита у детей. Вопросы практической педиатрии, 2014, № 6, т. 9, с. 30.
      11. Хавкин А. И., Комарова О. Н. Опыт применения Lactobacillus rhamnosus в педиатрии. Журнал международной медицины,№ 6(11), 2014, с. 101-106
     


    Full text is published :
    Khavkin A.I., Komoarova O.N. THE EFFECTIVENESS OF POLYCOMPONENT PROBIOTICS INCLUDING STRAINS OF LACTOBACILLUS ACIDOPHILUS LA-14, LACTOBACILLUS REUTERI AND BIFIDOBACTERIUM LACTIS IN FUNCTIONAL GASTROINTESTINAL DISORDERS IN EARLY AGED CHILDREN: THE RESULTS OF A PROSPECTIVE, OPEN, OBSERVATIONAL STUDY. Experimental and Clinical Gastroenterology Journal. 2017;141(05):57-64
    Read & Download full text